Nutex Health Q2 2026 Earnings: Arbitration Cost Relief Lifts Profit Despite Lower Revenue

Nutex Health (NASDAQ: NUTX) reported Q2 2026 revenue of $210.8 million, down 13.6% from $244.0 million, while diluted EPS improved to $9.38 from a loss of $2.95 per share. Net income attributable to Nutex Health reached $65.8 million, compared with a $17.7 million loss, as lower arbitration-related costs and stock-based compensation more than offset the revenue decline. Quarterly operating cash flow also increased to $34.2 million.

Core Performance Data

Revenue declined primarily because Hospital Division revenue fell and the prior-year period benefited from early improvements in the independent dispute resolution, or IDR, process. Profitability moved in the opposite direction as total operating costs and expenses declined to $69.5 million from $119.1 million, while corporate and other costs fell to $19.6 million from $91.2 million.

Adjusted EBITDA, a non-GAAP measure, increased 25.7% even though revenue contracted. Gross and operating margins expanded substantially, reflecting the unusually large expense reductions recorded during the quarter.

Consolidated net income was $96.3 million, of which $30.5 million was attributable to noncontrolling interests. The amount attributable to Nutex Health shareholders was therefore $65.8 million.

Business and Segment Performance

Hospital Division revenue decreased 14.6% to $201.9 million from $236.3 million, making it the main source of the consolidated revenue decline. Population Health Management revenue increased 15.8% to $8.9 million, but the division remained too small to offset the hospital decline.

Patient activity did not follow the same direction as revenue. Total Hospital Division visits increased 9.6% to 49,962, while same-hospital visits rose 6.3%. At the same time, same-hospital revenue fell 12.1%, indicating that higher patient volume did not translate into higher reported revenue during the quarter.

The company attributed most of the revenue decline to a difficult comparison with Q2 2025, when positive results from early-stage improvements in the IDR process were recognized. This makes IDR timing and collections important when interpreting the relationship between hospital visits and reported revenue.

Retroactive Arbitration Cost Relief Reversed the Revenue-Profit Relationship

The defining feature of the quarter was a $52.3 million reduction in arbitration-related contract services expense. Contract services expense fell to $1.1 million from $61.1 million, allowing gross profit to rise despite a $33.2 million decline in revenue.

The reduction reflected two changes. First, Nutex amended its agreement with HaloMD so that certain fees moved to a pay-on-collected basis retroactive to the original May 1, 2024 contract date. The amendment also revised service fees for federal and state settlements obtained on or after July 1, 2026. Second, the CMS administrative fee for the federal IDR process decreased from $115 to $15 per party per dispute, effective June 11, 2026.

Lower stock-based compensation provided another major year-over-year benefit. The expense fell to $2.9 million from $78.7 million, helping corporate and other costs decline sharply. By contrast, general and administrative expense rose to $16.7 million from $12.5 million.

The quarter’s expense benefit should not be treated as fully representative of the future run rate. Nutex expects the contractual and administrative changes to reduce normalized historical contract services expense by approximately 25% to 30% prospectively, which is materially smaller than the retroactive benefit recognized in Q2.

Nutex said it submits 50% to 60% of its claims through IDR. The company currently prevails in more than 85% of award determinations and collects, on average, more than 80% of awarded amounts. These figures help explain why IDR award timing, collections, and associated fees can have a material effect on reported results.

Profitability, Cash Flow, and Balance Sheet

Quarterly operating cash flow increased to $34.2 million from $27.3 million. For the first six months of 2026, operating cash flow was $109.7 million, up from $78.2 million in the comparable period. The six-month cash-flow statement classified the $52.3 million change in estimate as noncash, underscoring that the income statement benefit did not represent an equivalent current-period cash inflow.

Cash and cash equivalents increased to $205.2 million at June 30 from $185.6 million at the end of 2025. Long-term debt rose modestly to $31.1 million from $29.2 million. During the first half, Nutex used $50.7 million for stock repurchases and retirements and made $28.6 million of member distributions, contributing to $84.7 million of net financing cash outflows.

Accounts receivable increased by $32.2 million during the first half to $351.7 million. Although operating cash flow improved, the size and continued growth of receivables remain relevant because part of Nutex’s business model depends on completing the IDR process and collecting arbitration awards.

Outlook

Nutex provided quantitative operational and cost expectations rather than revenue or earnings forecasts. The anticipated contract services savings are based on the current regulatory environment and could differ from actual future expenses.

The amended HaloMD agreement also gives Nutex the option to conduct dispute-resolution services internally or use another provider for certain future facilities.

Recent Insider Transactions

The supplied transaction-level data lists four direct stock purchases and one derivative exercise in March 2026. However, the same source’s six-month aggregate reports zero purchases and zero sales, creating an internal inconsistency that investors should consider when reviewing these records.

No conclusion about management’s view of the company’s valuation can be drawn solely from these transactions.

Risks Investors Need to Watch

• IDR and regulatory uncertainty: Revenue, fees, and cash collections remain sensitive to the federal IDR process, regulatory changes under the No Surprises Act, and related litigation.
• Profit normalization: Q2 profitability benefited from a $52.3 million retroactive expense reduction and a large year-over-year decline in stock-based compensation. Future margin performance may be less pronounced once those comparison effects fade.
• Other expenses are rising: Payroll increased to $42.8 million from $36.3 million, while general and administrative, medical supplies, and other operating costs also increased. These costs could offset part of the expected arbitration-related savings.
• Receivables and collection timing: Accounts receivable reached $351.7 million, increasing the importance of converting IDR awards and other claims into cash.
• Expansion execution: Opening three hospitals later in 2026 could expand patient access, but it will also require Nutex to manage staffing, expenses, and revenue-cycle processes across a larger facility base.

Conclusion

Nutex Health’s Q2 2026 results featured lower revenue but sharply higher profit, primarily because retroactive arbitration-cost relief and lower stock-based compensation outweighed the hospital revenue decline. Patient visits and operating cash flow increased, while the balance sheet retained substantially more cash than long-term debt. The main issue for subsequent quarters is whether normalized contract services savings, IDR collections, and hospital expansion can sustain profitability after the quarter’s retroactive expense benefit passes.